Still tripping on TRIPS
If India, one of the main proponents of the TRIPS waiver, is left out, is it time for an ‘India waiver’ to show the way forward?
Author
Filling the gaps in India’s pharma manufacturing supply chain
The lessons of the past – of spiralling API costs, overdependence on a shrinking list of API makers – have been well learnt
India remains a key focus for UPS Healthcare
Having surpassed the 1 billion COVID-19 vaccines delivery milestone in December, Daniel Gagnon, Vice President, Marketing…
Why we need an Aatmanirbhar booster strategy
An Aatmanirbhar booster strategy will save lives. As a bonus, it will also boost long term development programmes at local…
With Omicron, the SARS-CoV-2 virus ups the ante
VOCs like Omicron are only to be expected as the divide between the vaccine haves and have-nots, and the Global North-South,…
Approved antibiotics and those under clinical development are insufficient to arrest AMR: Rex…
Flagging off World Antimicrobial Awareness Week from 18th to 24th November, Rex Clements, CEO, Centrient Pharmaceuticals, in an…
The Covaxin-WHO EUL saga
Manufacturers will need to cover all bases from the start, as the regulatory process will only get more stringent and competitive
India is the fastest growing market across the globe for Waters
Dr Udit Batra, CEO and President, Waters Corporation reviews his company's strategy to cope with the pandemic, and bounce back to…
Biocon Biologics-SII alliance should balance business and public health
As both leaders hint at the intangibles of the alliance, let's hope they make good their promise to both patients as well as…
Is India’s pharma sector being penalised for its success?
Leaving out pharma from the RoDTEP scheme is harsh but the message is that managing the COVID-19 situation in India takes…